Figure 1From: Phase IIb randomized trial of adjunct immunotherapy in patients with first-diagnosed tuberculosis, relapsed and multi-drug-resistant (MDR) TBThe proportion of ATT-treated patients in V5 and placebo arms who have benefited from the therapy according to the measured endpoints.Back to article page